EP3130233A1 - Verfahren zur herstellung von salzfreiem miso, salzfreies miso, leberfunktionsverbesserungsmittel und bluthochdruckverbesserungsmittel - Google Patents
Verfahren zur herstellung von salzfreiem miso, salzfreies miso, leberfunktionsverbesserungsmittel und bluthochdruckverbesserungsmittel Download PDFInfo
- Publication number
- EP3130233A1 EP3130233A1 EP15770313.3A EP15770313A EP3130233A1 EP 3130233 A1 EP3130233 A1 EP 3130233A1 EP 15770313 A EP15770313 A EP 15770313A EP 3130233 A1 EP3130233 A1 EP 3130233A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- salt
- miso
- free miso
- free
- hepatic function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000294411 Mirabilis expansa Species 0.000 title claims abstract description 113
- 235000015429 Mirabilis expansa Nutrition 0.000 title claims abstract description 113
- 235000013536 miso Nutrition 0.000 title claims abstract description 113
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 25
- 230000003908 liver function Effects 0.000 title claims abstract description 11
- 230000006872 improvement Effects 0.000 title abstract description 5
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 54
- 244000068988 Glycine max Species 0.000 claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 18
- 230000002440 hepatic effect Effects 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 230000003405 preventing effect Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 26
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 26
- 239000000796 flavoring agent Substances 0.000 description 22
- 235000019634 flavors Nutrition 0.000 description 22
- 241000209094 Oryza Species 0.000 description 20
- 235000007164 Oryza sativa Nutrition 0.000 description 20
- 235000009566 rice Nutrition 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 18
- 235000014347 soups Nutrition 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- VVJYUAYZJAKGRQ-BGZDPUMWSA-N 1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)C1 VVJYUAYZJAKGRQ-BGZDPUMWSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000000384 rearing effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000009530 blood pressure measurement Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- -1 micropellets Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/11—Preparation or pretreatment of starting material involving culturing conditions, e.g. cultivation in the dark or under defined water stress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Definitions
- This invention relates to a method of producing salt-free miso having a good taste and flavor, which method also is capable of shortening the production process, and to salt-free miso.
- the invention additionally relates to a hepatic function-improving agent and to a hypertension-ameliorating agent.
- Miso is known to take a long time to produce. Lately, given the trends toward shorter working hours and increased vacation time, there has been a desire for the development of an efficient method of making miso at the production site.
- the largest bottleneck in developing an efficient method of production without having to invest in plant and equipment is the fermentation step. Shortening the length of the fermentation step has a large effect on all the operations in that it shortens the production time.
- Conventional fermentation operations are carried out over an extended period of time at a low temperature so as not to deactivate the koji ( Aspergillus oryzae ). Because the production process is long, common salt or alcohol is often added to prevent other types of microorganisms from growing during the production process.
- Patent Document 1 JP-A S64-4743
- one object of the invention is to provide a method of producing salt-free miso that can shorten the production process. Another object is to provide salt-free miso having a good taste and flavor that is produced by such a method. Further objects are to provide a hepatic function-improving agent and a hypertension-ameliorating agent that use this salt-free miso.
- the inventors have conducted extensive investigations, as a result of which they have discovered that by using steamed soybeans as the starting material and reacting the steamed soybeans with koji culture under applied heat and pressure, salt-free miso having a good taste and flavor can be obtained, in addition to which the production process can be shortened.
- the inventors have found that the resulting salt-free miso has an excellent hepatic function-improving effect and excellent hypertension-ameliorating and preventing effects.
- the invention provides the following method of producing salt-free miso, the following salt-free miso, and the following hepatic function-improving agent and hypertension-ameliorating agent.
- the production method of the invention enables salt-free miso having a good taste and flavor to be obtained, and moreover is able to shorten the production process.
- this production method enables an excellent hepatic function-improving agent and an excellent hypertension-ameliorating agent to be provided.
- the salt-free miso production method of the invention involves reacting steamed soybeans with koji culture under applied heat and pressure.
- Miso is generally defined as a product containing soybeans, koji culture and salt.
- salt-free miso refers to a product which contains soybeans and koji culture but does not contain salt; contains soybeans and koji culture.
- Steamed soybeans serve as a starting material in the production method of the invention. When boiled soybeans are used, a loss of flavor occurs and so the good flavor intended is not obtained.
- the soybeans are not particularly limited; use may be made of commonly sold soybeans.
- the soybeans are soaked in water before being steamed. Soaking is not particularly limited, so long as sufficient water is contained within the soybeans. Soaking should be carried out by completely immersing the soybeans in water and soaking them at a temperature of 10 to 30°C for 5 to 20 hours, and preferably 10 to 12 hours.
- the method of steaming is not particularly limited. Steamed soybeans may be obtained by using a steamer to steam the soybeans for 0.5 to 2 hours.
- a known apparatus such as a mixer or chopper may be used for this purpose.
- the processing time, etc. may be selected as appropriate, although processing to a minced or other state in which pieces of the steamed soybeans remain after processing is desirable.
- the applied heat and pressure conditions include a pressure of preferably 40 to 100 MPa, and more preferably 50 to 80 MPa. Alternatively, the pressure may be set to from 50 to 70 MPa.
- the temperature is preferably from 40 to 70°C, and more preferably from 50 to 60°C.
- the koji ( A. oryzae ) is not particularly limited.
- Exemplary koji cultures include those obtained from grains such as rice or wheat or from beans.
- One such koji culture may be used alone, or two or more may be suitably selected and used together.
- the length of the fermentation step is preferably at least one day and may be at least two days or at least three days, with a period of one to five days being more preferred. Setting this period to at least one day allows the reaction to proceed to a sufficient degree. However, when the length of this step exceeds seven days, the miso may turn brown.
- this production method enables salt-free miso having a good taste and flavor to be obtained without adding salt, and moreover contains no harmful microorganisms, there is no need to include salt or ethanol for the sake of preservation.
- the amount of salt included in the miso may be suitably set according to consumer preferences or the miso may be free of added salt.
- the deterioration of hepatic function is divided into conditions caused largely by alcohol and conditions not caused by alcohol.
- the indicators of improvement in hepatic function when deterioration in hepatic function is not attributable to alcohol are the hepatic function-related substances GOT and GPT.
- Deterioration in hepatic function due to decreased sugar metabolism and decreased fat metabolism is also known.
- the salt-free miso of the invention as demonstrated in the subsequently described working examples, has been confirmed to have triglyceride-lowering, cholesterol-lowering, glucose-lowering and GPT-lowering effects and to maintain the liver weight when on a high-fat diet, and therefore is effective as a hepatic function-improving agent.
- the amount taken daily by one adult is preferably from 0.01 to 10 g, and more preferably from 0.1 to 5 g. The advantageous effects are better exhibited when taken in this range.
- the amount of salt-free miso included in the hepatic function-improving agent is suitably set within the range of 0.1 to 10 wt%.
- the hepatic function-improving agent of the invention can be prepared as, for example, a nutraceutical, a specially designated health food, a quasi-drug, or a pharmaceutical preparation.
- the method in which it is taken (administered) is not particularly limited, and may be, for example, internal (e.g. oral) or external. Oral intake is preferred.
- the manner of use is not particularly limited; for example, this agent may be taken before or after meals or before going to bed.
- the dosage form is not particularly limited, and includes internal preparations such as granules, micropellets, powders, tablets, capsules, solutions, emulsions and suspensions; and external preparations such as lotions, ointments and poultices.
- the hepatic function-improving agent of the invention may include ordinary amounts of any ingredients commonly used in such agents, insofar as doing so does not detract from the advantageous effects of the invention.
- the salt-free miso of the invention is effective as a hypertension-ameliorating agent.
- the hypertension-ameliorating agent of the invention can also be used for the prevention of hypertension.
- the amount taken daily by one adult is preferably from 0.01 to 10 g, and more preferably from 0.1 to 5 g. The advantageous effects are better exhibited when taken in this range.
- the amount of salt-free miso included in the hypertension-ameliorating agent is suitably set within the range of 0.1 to 10 wt%.
- the hypertension-ameliorating agent of the invention can be prepared as, for example, a nutraceutical, a specially designated health food, a quasi-drug, or a pharmaceutical preparation.
- the method in which it is taken (administered) is not particularly limited, and may be, for example, internal (e.g. oral) or external. Oral intake is preferred.
- the manner of use is not particularly limited; for example, this agent may be taken before or after meals or before going to bed.
- the dosage form is not particularly limited, and includes internal preparations such as granules, micropellets, powders, tablets, capsules, solutions, emulsions and suspensions; and external preparations such as lotions, ointments and poultices.
- the hypertension-ameliorating agent of the invention may include ordinary amounts of any ingredients commonly used in such agents, insofar as doing so does not detract from the advantageous effects of the invention.
- the resulting salt-free miso was placed within a vessel in an amount normally used to prepare miso soup, and table salt was added to a salt concentration in the miso soup of 0.8 wt%.
- This miso soup was compared with a comparative miso soup (adjusted to a salt concentration of 0.8 wt%) prepared using commercial miso (Masuya Miso KK).
- a taste comparable to that of the comparative miso soup was obtained and the flavor was better than that of the comparative miso soup.
- the salt-free miso clearly was perfectly satisfactory as a miso.
- the rearing conditions were set as follows. Temperature: 22 ⁇ 3°C; humidity: 55 ⁇ 15%; ventilation: constant all-fresh air system; illumination: 12 hours/day (6:00 AM to 6:00 PM). The animals were kept individually in plastic rearing cages.
- the water supplied was Fukuyama City tap water which was given freely to the animals with an automatic waterer.
- a control group (8 rats) and a salt-free miso group (8 rats).
- Ad libitum feeding was continued for six weeks. The animals were fasted for 5 hours before the end of the trial, after which blood was drawn from a vein and the triglyceride (TG), total cholesterol, glucose and GPT levels were measured by Dry Chem (Fujifilm Corporation). Following the end of the trial, the liver was removed and weighed.
- TG triglyceride
- glucose and GPT levels were measured by Dry Chem (Fujifilm Corporation).
- the rearing conditions were set as follows. Temperature: 22 ⁇ 3°C; humidity: 55 ⁇ 15%; ventilation: constant, all-fresh air system; illumination: 12 hours/day (6:00 AM to 6:00 PM). The animals were held three to a plastic rearing cage.
- Formula feed having the composition shown in Table 1 below was used.
- the water supplied to the animals was Fukuyama City tap water which was given freely to each animal with an automatic waterer.
- Corn oil 10.0 8.5
- Vitamin mixture 1.0
- Salt mixture 3.5
- Cellulose 5.0 4.0
- Sucrose 18.7 18.7
- Cornstarch 37.2
- Sodium chloride 1.0
- Cholesterol 0.5 0.5 Sodium cholate 0.1 0.1 Salt-free miso 0 10.0
- mice After quarantining and acclimatization, the 20 animals were divided into two groups: a control group (10 rats) and a salt-free miso group (10 rats). Ad libitum feeding was continued for 11 weeks. The amounts of feed consumed are indicated below.
- the blood pressure from the caudal artery was measured using an MK-2000 non-heating, non-invasive blood pressure monitor for rats (Muromachi Kikai Co., Ltd.). Pressure measurements in consecutive administration trials were carried out each Monday before noon. Prior to measurement, the rat immobilizer was warmed and measurement was carried out in a non-stressful state.
- the blood pressure measurement results are shown in FIG. 7 .
- the salt-free miso group was confirmed to have a lowered blood pressure, demonstrating a hypertension-ameliorating effect.
- the change in body weight is shown in FIG. 8 . Because there was no observable difference in body weight between the control group and the salt-free miso group, salt-free miso does not appear to affect growth.
- "0" number of days refers to before administration of the test substance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Agronomy & Crop Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014063950A JP6394025B2 (ja) | 2013-06-11 | 2014-03-26 | 無塩味噌の製造方法及び無塩味噌、ならびに肝機能改善剤 |
PCT/JP2015/050103 WO2015146206A1 (ja) | 2014-03-26 | 2015-01-06 | 無塩味噌の製造方法及び無塩味噌、並びに肝機能改善剤及び高血圧改善剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3130233A1 true EP3130233A1 (de) | 2017-02-15 |
EP3130233A4 EP3130233A4 (de) | 2017-11-22 |
EP3130233B1 EP3130233B1 (de) | 2020-02-19 |
Family
ID=54198794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15770313.3A Active EP3130233B1 (de) | 2014-03-26 | 2015-01-06 | Verfahren zur herstellung von salzfreiem miso, salzfreies miso, leberfunktionsverbesserungsmittel und bluthochdruckverbesserungsmittel |
Country Status (4)
Country | Link |
---|---|
US (1) | US10111920B2 (de) |
EP (1) | EP3130233B1 (de) |
JP (1) | JP6394025B2 (de) |
WO (1) | WO2015146206A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6455150B2 (ja) * | 2015-01-06 | 2019-01-23 | 丸善製薬株式会社 | 高血圧改善剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS613345Y2 (de) * | 1980-07-12 | 1986-02-01 | ||
JP2538262B2 (ja) | 1987-06-29 | 1996-09-25 | コニカ株式会社 | ハロゲン化銀カラ−写真感光材料 |
JP3593354B2 (ja) * | 1993-10-14 | 2004-11-24 | カワタ工業株式会社 | 固体麹の純粋培養方法及び装置 |
EP0834262A4 (de) * | 1996-04-10 | 1999-03-24 | Nichimo Kk | Stoff mit einer gesundheitsverbessernden komponente und verfahren zu seiner herstellung |
JP2000270799A (ja) | 1999-03-25 | 2000-10-03 | Hideo Tsuyuki | 味噌原料用大豆の高圧処理法 |
JP4854841B2 (ja) * | 2000-09-18 | 2012-01-18 | 株式会社東洋発酵 | 肝障害低減剤 |
JP2006094747A (ja) * | 2004-09-29 | 2006-04-13 | Ajinomoto Co Inc | 抗肥満作用を有する組成物及び飲食品 |
JP2006070015A (ja) * | 2004-11-22 | 2006-03-16 | Ina Food Ind Co Ltd | 無塩味噌若しくは減塩味噌又はこれらの抽出物含有機能性組成物 |
JP4878771B2 (ja) * | 2005-04-19 | 2012-02-15 | 丸善製薬株式会社 | 表皮角化細胞増殖剤、及びその用途 |
JP2007006834A (ja) * | 2005-07-01 | 2007-01-18 | Marukome Kk | 味噌及び味噌食品の製造方法 |
JP4809785B2 (ja) * | 2006-09-08 | 2011-11-09 | ヒガシマル醤油株式会社 | 醤油に含まれる高分子物質の用途 |
JP4794486B2 (ja) * | 2007-03-20 | 2011-10-19 | 株式会社喜源バイオジェニックス研究所 | 培地兼用発酵食品及びその製造方法 |
CN102485031A (zh) * | 2010-12-02 | 2012-06-06 | 高巍 | 无盐酱油 |
-
2014
- 2014-03-26 JP JP2014063950A patent/JP6394025B2/ja active Active
-
2015
- 2015-01-06 WO PCT/JP2015/050103 patent/WO2015146206A1/ja active Application Filing
- 2015-01-06 EP EP15770313.3A patent/EP3130233B1/de active Active
- 2015-01-06 US US15/128,742 patent/US10111920B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3130233A4 (de) | 2017-11-22 |
EP3130233B1 (de) | 2020-02-19 |
WO2015146206A1 (ja) | 2015-10-01 |
US10111920B2 (en) | 2018-10-30 |
JP6394025B2 (ja) | 2018-09-26 |
US20170100444A1 (en) | 2017-04-13 |
JP2015015941A (ja) | 2015-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alegbejo | Nutritional value and utilization of Amaranthus (Amaranthus spp.)–a review | |
KR102143376B1 (ko) | 갈색거저리를 포함하는 환자용 죽 및 이의 제조방법 | |
KR20190104817A (ko) | 고함량 아베난쓰라마이드를 포함하는 귀리 추출물의 제조 방법 | |
KR102549413B1 (ko) | 탈모 치료용 조성물의 제조 방법 | |
HaÅ et al. | The effect of addition bee pollen to feed mixtures on internal fat of broiler Ross 308 | |
WO2004075905A1 (ja) | 筋肉増強剤および筋肉減衰の予防または治療剤 | |
Srivastava et al. | Dynamic bioactive properties of nutritional superfood Moringa oleifera: A comprehensive review | |
CN104187669B (zh) | 一种具有祛斑美容功能的营养食品及其制备方法 | |
CN1777420A (zh) | 用于预防和/或改善与生活方式相关疾病的经加工的油脂组合物 | |
EP3130233B1 (de) | Verfahren zur herstellung von salzfreiem miso, salzfreies miso, leberfunktionsverbesserungsmittel und bluthochdruckverbesserungsmittel | |
US20030228348A1 (en) | Health food and preparation having an anti-obesity effect | |
KR20170086196A (ko) | 미강 조성물 및 발효 미강 조성물의 제조방법 | |
KR101939535B1 (ko) | C3g 성분 함유 사료첨가제 및 그의 제조방법 | |
JP2011037811A (ja) | 脂肪低減用組成物 | |
JP6455150B2 (ja) | 高血圧改善剤 | |
EP1864658A1 (de) | Mittel zur linderung von gefässinsuffizienz | |
JP7170357B2 (ja) | 育毛・発毛用外用剤 | |
JP2003137796A (ja) | 肝機能保護剤または改善剤 | |
KR101273276B1 (ko) | 커큐민을 첨가한 가축용 사료의 제조방법 및 상기 방법으로 제조된 가축용 사료 | |
CN108740830A (zh) | 一种茯茶卤鸡蛋及其制备方法 | |
EP4309514A1 (de) | Schweinefettextrakt, verfahren zur gewinnung, zusammensetzungen damit und verwendungen davon | |
JP2014181214A (ja) | ドパミン産生促進剤 | |
KR101168584B1 (ko) | 알로에를 함유한 고추장의 제조 방법 및 이에 따른 고추장 | |
KR20160083808A (ko) | 쓴메밀을 유효성분으로 함유하는 생활습관병 또는 간질환 예방 또는 개선용 건강기능식품 조성물 | |
CN105614846A (zh) | 一种硒蛋白磷脂保健品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20161004 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 1/16 20060101ALI20171012BHEP Ipc: A61P 9/12 20060101ALI20171012BHEP Ipc: A61K 36/062 20060101ALI20171012BHEP Ipc: A23L 33/10 20160101ALI20171012BHEP Ipc: A23L 11/20 20160101ALI20171012BHEP Ipc: A61K 36/48 20060101AFI20171012BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20171020 |
|
17Q | First examination report despatched |
Effective date: 20190114 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602015047347 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A23L0011200000 Ipc: A61K0036480000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 1/16 20060101ALI20190916BHEP Ipc: A23L 33/10 20160101ALI20190916BHEP Ipc: A61P 9/12 20060101ALI20190916BHEP Ipc: A23L 11/00 20160101ALI20190916BHEP Ipc: A61K 36/48 20060101AFI20190916BHEP Ipc: A61K 36/062 20060101ALI20190916BHEP |
|
INTG | Intention to grant announced |
Effective date: 20191007 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE FR |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE FR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602015047347 Country of ref document: DE Owner name: MASUYAMISO CO. LTD., KURE-SHI, JP Free format text: FORMER OWNER: MARUZEN PHARMACEUTICALS CO., LTD., ONOMICHI-SHI, HIROSHIMA, JP Ref country code: DE Ref legal event code: R081 Ref document number: 602015047347 Country of ref document: DE Owner name: MARUZEN PHARMACEUTICALS CO., LTD., ONOMICHI-SH, JP Free format text: FORMER OWNER: MARUZEN PHARMACEUTICALS CO., LTD., ONOMICHI-SHI, HIROSHIMA, JP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015047347 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015047347 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20201120 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20221216 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240122 Year of fee payment: 10 |